10 or 15 mg once weekly) vs Reduce to tirzepatide 5 mg once weekly vs Placebo for 52 weeks (randomized 3:3:2 at week 60) Primary outcome: Percent change in bodyweight from baseline to week 112 Results: Primary outcome (percent change in bodyweight at week 112): Tirzepatide MTD -21.9%, Tirzepatide 5 mg -16.6%, Placebo -9.9% (estimated treatment difference vs placebo -12.0% for MTD and -6.6% for 5 mg
F.G.: AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Lifescan, Medimmune, Merck Sharp & Dohme, Medtronic, Novo Nordisk, Roche Diabetes Care, Sanofi Aventis
Permeability of the blood-brain barrier to a novel satiety molecule nesfatin-1
Researchers found an association between the use of GLP-1s and a higher risk for the condition, called ischemic optic neuropathy, although the risk remained low
In order to enhance the applicability of this in vitro model, the effect of shear stress could be combined with other relevant triggers, such as hyperglycemia
Combination (CagriSema) : Developed by Novo Nordisk